The next major catalyst is the Phase 3 CATT1 topline data readout in mid 2027. Monitor cash runway updates and any partnering discussions for HPPD, which could provide non-dilutive funding.
Drugs in focus
VTVT drug pipeline →cadisegliatin
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 CATT1 results are positive (mid 2027), an FDA submission (NDA) would likely follow in late 2027 or 2028, with potential approval in 2028-2029, assuming no regulatory setbacks.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 3 CATT1 topline data readout expected around mid 2027, roughly 7 months away. Positive results would validate cadisegliatin as the first oral adjunctive therapy for T1D and could drive a significant re-rating given the stock's current valuation near its 52-week low. Negative results or delays would be severely punishing for this single-asset company. Interim updates, partnership news, or early Phase 2a Hybrid CATT1 pilot data could provide nearer-term trading catalysts.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $21.03entry
- T+1 · 8d ago +0.71%α −1.65% · $21.18
- T+5 · 4d ago −6.37%α −8.97% · $19.69
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
vTv Therapeutics reported a Q3 2026 net loss of $11.6M ($0.94 per share), wider than the $8.7M loss a year ago, with zero revenue. The key event is the completion of enrollment in the Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes, with topline results expected in mid 2027. The company has $77.2M in cash, which it expects to fund operations through that readout.
Key Financial Metrics
Key Facts
- Phase 3 CATT1 trial enrollment completed with 166 participants randomized; topline results expected mid 2027
- Cash and cash equivalents $77.2M as of September 30, 2026, down from $88.9M at December 31, 2025
- Net loss attributable to vTv shareholders was $11.6M ($0.94 per share) for Q3 2026 vs $8.7M ($1.08 per share) for Q3 2025
- R&D expenses $7.5M in Q3 2026 vs $7.0M in Q3 2025, driven by Phase 3 CATT1 investment
- FDA granted Orphan Drug Designation to HPPD for sickle cell disease in October 2026
- First participant randomized in Phase 2a Hybrid CATT1 pilot study for cadisegliatin in hybrid closed-loop insulin delivery systems
Financial Impact
Cash burn of ~$11.7M from Dec 2025 to Sep 2026; net loss of $11.6M in Q3 2026
Risk Factors
- Phase 3 CATT1 trial may fail to meet primary endpoint, wiping out the lead pipeline asset
- Cash burn rate may require additional financing before mid 2027 if expenses increase or timelines slip
- Zero revenue; fully dependent on clinical trial success and potential partnerships
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3397006 |
Track record
9 reports on VTVT
Filters
- Nov 16, 2026today SC 13D/A Neutral 3/10 Entry $17.69 Now $17.69 +0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $19.69 Now $17.69 −10.16% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Viewing Entry $21.03 Now $17.69 −15.88% settles Dec 7
- Oct 8, 20265w ago SC 13G/A Neutral 3/10 Entry $31.18 to $21.03 Now $17.69 −43.26% ▼ −32.55% −26.99% vs SPY
- Jun 10, 202622w ago DEFA14A Neutral 3/10 Entry $31.59 to $33.44 Now $17.69 −44.00% ▲ +5.86% +3.97% vs SPY
- May 8, 202627w ago Press Release Neutral 2/10 Entry $30.46 to $31.77 Now $17.69 −41.92% ▲ +4.30% +4.61% vs SPY
- Mar 10, 202635w ago Press Release Mixed 6/10 Entry $35.10 to $37.30 Now $17.69 −49.60% ▲ +6.27% +5.74% vs SPY
- Feb 26, 202637w ago 8-K Neutral 4/10 Entry $39.32 to $37.80 Now $17.69 −55.01% ▼ −3.87% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers